The lipid and non-lipid effects of statins

This publication has 149 references indexed in Scilit:

• Coronary Heart Disease in Patients With Low LDL-Cholesterol
  Circulation, 2002
• Modulation of COX-2 Expression by Statins in Human Aortic Smooth Muscle Cells
  Published by Elsevier ,2001
• New Evidence for Beneficial Effects of Statins Unrelated to Lipid Lowering
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2001
• Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice
  Stroke, 2000
• Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells
  Life Sciences, 2000
• Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)
  The American Journal of Cardiology, 1999
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line
  International Journal of Immunopharmacology, 1996
• Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors
  Clinical Pharmacokinetics, 1996
• Diurnal variation of HMG-CoA reductase activity in rat liver peroxisomes
  Biochemical and Biophysical Research Communications, 1987